An interventional study of Functional Motor Disorder-Specific Multidisciplinary Rehabilitation and Conventional Multiple Sclerosis Rehabilitation in Multiple Sclerosis and Functional Neurological Disorders, sponsored by IRCCS San Raffaele. Not yet recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by IRCCS San Raffaele · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.
Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 86th largest by planned enrollment of the 230 interventional ones that give a count, is one of 11 that started in 2026, is one of 105 with no phase, reaches primary completion later than 81 of the 89 other live ones, and was the 287th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:
University of Catania · Sites in Italy
Ages 20–40 · Healthy volunteers
Ciceri Fabio · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18–65
Sanofi · Sites in Italy, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 40 · Phase 3 66 · Phase 4 19
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 115 across the 230 interventional studies, 214 across the 59 observational. Of the 164 that completed or were terminated, 77 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 289 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 9 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT05748015Istituti Clinici Scientifici Maugeri SpADefinition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis | 2026-11-30 |
| NCT07502066IRCCS San Camillo, Venezia, ItalyClinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases | 2026-12 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 289 studies in Multiple Sclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that may cause a broad range of motor and non-motor symptoms. New or worsening neurological symptoms in people with MS are frequently interpreted as a possible relapse. However, relapse-like episodes are not always caused by new inflammatory disease activity and may instead reflect infection, fever, comorbidities, fluctuations of pre-existing symptoms, or an overlapping functional neurological disorder. Functional motor disorders (FMDs) are characterized by altered voluntary motor control and may present with weakness, tremor, gait disturbance, postural instability, abnormal movements, or impaired motor performance. These manifestations may resemble MS-related symptoms and may coexist with established structural neurological disease. In people with MS, functional motor symptoms may therefore be misclassified as relapse or disease progression, potentially leading to unnecessary investigations, corticosteroid treatment, inappropriate escalation of disease-modifying therapy, avoidable healthcare use, and delayed access to appropriate rehabilitation. Despite growing recognition of FMD-MS overlap, its prevalence, clinical characteristics, and optimal management remain insufficiently defined. This multicenter prospective study aims to improve the identification, characterization, and management of FMD-MS overlap in people with MS presenting with acute neurological symptom worsening. The study consists of two sequential and interconnected parts.
Part A is an observational, cross-sectional diagnostic and prevalence study. A total of 192 adults with MS according to the 2017 revisions of the McDonald criteria and reporting new or worsening neurological symptoms within the previous 30 days will be enrolled at two tertiary MS centers in Italy. No study-assigned treatment will be administered during Part A. Participants will undergo a standardized multidimensional assessment including demographic and MS-related clinical information, neurological examination, evaluation of positive functional motor signs, disability and functional measures, gait and balance assessments, patient-reported outcome measures, and review of laboratory and magnetic resonance imaging findings obtained as part of routine clinical care when clinically indicated.
The primary aim of Part A is to estimate the prevalence of FMD-MS overlap, also referred to in the protocol as functional pseudorelapse, among people with MS presenting with acute symptom worsening. Additional aims are to distinguish FMD-MS overlap from true MS relapse and other causes of symptom worsening and to identify demographic, clinical, functional, gait, balance, psychological, quality-of-life, and routine-care imaging characteristics associated with each diagnostic category.
Part B is a pilot randomized, assessor-blinded, active-controlled rehabilitation study. Approximately 26 participants with confirmed FMD-MS overlap identified during Part A and meeting the additional rehabilitation eligibility criteria will enter Part B. These 26 participants are included within the overall cohort of 192 participants and are not an additional study population.
Participants entering Part B will be randomized in a 1:1 ratio to either a targeted FMD-specific multidisciplinary rehabilitation programme or conventional MS rehabilitation. The experimental programme will include five consecutive days of in-person rehabilitation focused on education regarding functional symptom mechanisms, movement retraining using attentional-redirection strategies, and development of an individualized self-management plan. This will be followed by a 12-week home-based programme supported by weekly telemedicine sessions. The active comparator will consist of conventional MS rehabilitation addressing mobility, strength, gait, balance, endurance, fatigue management, and functional independence, without protocolized FMD-specific techniques.
Part B aims to assess the feasibility, safety, and preliminary efficacy of the FMD-specific rehabilitation programme compared with conventional MS rehabilitation. Outcomes will be assessed at baseline, immediately after the five-day intervention, and at three months. The main efficacy outcome will be change in functional motor symptom severity, with additional evaluation of disability, functional performance, gait, balance, fatigue, pain, emotional functioning, quality of life, healthcare utilization, and costs.
Overall, the study is expected to provide prospective evidence on the frequency and clinical profile of FMD-MS overlap and preliminary evidence on whether a mechanism-specific rehabilitation approach may improve outcomes in affected people with MS.
This multicenter prospective study is conducted at two tertiary multiple sclerosis (MS) centers in Italy and uses a sequential design combining an observational diagnostic phase with a nested randomized rehabilitation trial. The study addresses the clinical difficulty of distinguishing inflammatory MS relapse from functional motor symptoms in people with established MS. Functional motor disorder (FMD) may coexist with MS and produce weakness, tremor, gait disturbance, postural instability, or other motor manifestations that resemble relapse or progression. Misclassification may result in unnecessary investigations or anti-inflammatory treatment and may delay access to mechanism-specific rehabilitation.
In Part A, 192 consecutive adults with MS presenting with self-reported acute neurological symptom worsening within the previous 30 days will undergo a standardized, cross-sectional multidimensional assessment. Part A is observational, and no study intervention will be assigned. The assessment will integrate neurological examination, positive clinical signs of FMD, functional and patient-reported evaluations, gait and balance measures, and laboratory or magnetic resonance imaging findings obtained as part of routine clinical care when clinically indicated.
Participants will be classified as having a true MS relapse, FMD-MS overlap or functional pseudorelapse, or another clinically relevant explanation for symptom worsening. A true relapse will be defined according to the occurrence of new or worsening neurological symptoms lasting at least 24 hours in the absence of fever, active infection, trauma, or another acute medical cause. FMD-MS overlap will be established using positive signs of functional motor dysfunction together with applicable DSM-5 and Gupta-Lang criteria. Complex or borderline cases may undergo central diagnostic review to improve consistency between centers. Routine clinical decisions regarding investigations and management of the presenting episode will remain under the responsibility of the treating physician.
Part A will estimate the prevalence of FMD-MS overlap in this clinical population and characterize the multidimensional features associated with the different diagnostic classifications. The planned sample of 192 participants allows for incomplete assessments while providing approximately ±5% precision around an expected prevalence of 13%.
In Part B, participants identified during Part A as having confirmed FMD-MS overlap will be evaluated for suitability for the rehabilitation trial. Approximately 26 participants are expected to proceed to Part B. These participants form a subgroup of the 192 participants enrolled in Part A and are therefore not additional to the overall study enrollment. Participants who do not proceed to Part B will complete their study participation after Part A, while their data will remain included in the observational analyses.
Part B is a pilot, randomized, assessor-blinded, parallel-group, active-controlled trial. After confirmation of eligibility and completion of baseline assessments, participants will be randomized in a 1:1 ratio to targeted FMD-specific multidisciplinary rehabilitation or conventional MS rehabilitation. The allocation sequence will be computer-generated and concealed until treatment assignment. Participants and treating therapists cannot be blinded because of the nature of the interventions; however, outcome assessments will be conducted by evaluators unaware of treatment allocation.
The experimental programme combines a short, intensive in-person intervention with continued home-based self-management and structured telemedicine support. It is based on FMD-specific principles, including explanation of functional symptom mechanisms, identification and therapeutic use of positive functional signs, movement retraining through attentional redirection, and restoration of more automatic motor control. The active comparator consists of conventional MS neurorehabilitation addressing mobility, strength, gait, balance, endurance, fatigue management, and functional independence, without protocolized FMD-specific techniques.
Part B is intended to evaluate the feasibility, safety, and preliminary clinical effects of the targeted programme rather than provide definitive confirmatory evidence of efficacy. Analyses will primarily follow the intention-to-treat principle, with complementary per-protocol analyses where appropriate. Given the pilot sample size, interpretation will emphasize recruitment, adherence, retention, data completeness, outcome variability, effect estimates, and confidence intervals. Together, the two study parts are designed to establish the clinical relevance of FMD-MS overlap and generate evidence needed to plan a larger definitive rehabilitation trial.
Inclusion Criteria for Part A - Observational Diagnostic and Prevalence Phase
Participants must meet all of the following criteria:
Additional Inclusion Criteria for Part B - Randomized Interventional Rehabilitation Phase
To proceed to Part B, participants must additionally meet all of the following criteria:
Exclusion Criteria Exclusion Criteria for Part A - Observational Diagnostic and Prevalence Phase
Participants meeting any of the following criteria will be excluded from Part A:
Additional Exclusion Criteria for Part B - Randomized Interventional Rehabilitation Phase
Participants meeting any of the following criteria will not proceed to Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants will initially undergo the Part A observational diagnostic and prevalence assessment. This group comprises participants who complete Part A but do not proceed to Part B because FMD-MS overlap is not confirmed, the additional Part B eligibility criteria are not met, or the participant does not enter the randomized rehabilitation phase. No study rehabilitation intervention will be assigned. Study participation will end after completion of the Part A assessment.
Participants will first complete the Part A observational assessment. Participants with confirmed FMD-MS overlap who meet the additional Part B eligibility criteria and are randomized to the experimental arm will receive five consecutive days of in-person FMD-specific multidisciplinary rehabilitation, approximately two hours per day. This will be followed by a 12-week home-based self-management programme, approximately one hour per day, three days per week, and one weekly 30-minute telemedicine session.
Other: Functional Motor Disorder-Specific Multidisciplinary Rehabilitation
Participants will first complete the Part A observational assessment. Participants with confirmed FMD-MS overlap who meet the additional Part B eligibility criteria and are randomized to the active comparator will receive conventional multiple sclerosis rehabilitation representing current standard rehabilitative care. Treatment will address mobility, muscle strength, gait, balance, endurance, fatigue management, and functional independence.
Other: Conventional Multiple Sclerosis Rehabilitation
A mechanism-based multidisciplinary rehabilitation programme adapted for people with multiple sclerosis and overlapping functional motor symptoms. The programme includes education regarding functional symptom mechanisms; exploration of the influence of symptoms on posture and movement; demonstration of positive functional motor signs where clinically appropriate; movement retraining using attentional redirection, graded functional exercises, external cues, dual-task or distraction strategies, visual or video feedback, and task-oriented activities; and development of an individualized self-management plan. The intervention comprises five consecutive days of supervised in-person rehabilitation, approximately two hours per day, followed by 12 weeks of home-based exercises and weekly telemedicine support.
Also known as: FMD-specific rehabilitation, Functional movement retraining, FMD-targeted multidisciplinary rehabilitation
Standard neurorehabilitation for people with multiple sclerosis, individualized according to clinical needs and usual practice. Treatment may include strengthening, mobility exercises, gait and balance training, graded exercise, endurance training, fatigue-management strategies, and activities intended to improve functional independence. The programme will not include protocolized education regarding functional symptom mechanisms, therapeutic demonstration of positive functional motor signs, attentional-redirection-based movement retraining, or a formal FMD-specific self-management programme.
Also known as: Standard multiple sclerosis rehabilitation, Conventional neurorehabilitation, Usual rehabilitation care for multiple sclerosis
Prevalence of Functional Motor Disorder-Multiple Sclerosis Overlap Among Participants Presenting With Acute Neurological Symptom Worsening
The number and percentage of evaluable participants in Part A who are classified as having Functional Motor Disorder-Multiple Sclerosis overlap, also referred to in the protocol as functional pseudorelapse. Classification will be based on the prespecified multidimensional diagnostic algorithm, including neurological examination, positive clinical signs of functional motor disorder, applicable DSM-5 and Gupta-Lang diagnostic criteria, and routine-care investigations when clinically indicated. Prevalence will be calculated as the number of participants meeting the diagnostic criteria for FMD-MS overlap divided by the total number of evaluable participants enrolled in Part A and will be reported with a 95% confidence interval.
Time frame: At Part A enrollment, following completion of the diagnostic assessment and within 30 days of onset of acute neurological symptom worsening
Change From Baseline in Simplified Functional Movement Disorders Rating Scale Score Immediately After the 5-Day Rehabilitation Program
Change in functional motor symptom burden measured using the Simplified Functional Movement Disorders Rating Scale (S-FMDRS). The scale provides a clinician-rated assessment of the anatomical distribution, severity, duration, and functional impact of functional motor symptoms, with higher scores indicating a greater functional motor symptom burden. Change will be calculated as the post-intervention score minus the Part B baseline score; a negative change indicates improvement. The change from baseline will be compared between the FMD-specific multidisciplinary rehabilitation arm and the conventional MS rehabilitation arm.
Time frame: From Part B baseline before randomization to immediately after completion of the 5-day rehabilitation program, at Day 5/6 ±2 days
Change From Baseline in Simplified Functional Movement Disorders Rating Scale Score at 3 Months
Change in functional motor symptom burden measured using the S-FMDRS. Change will be calculated as the 3-month score minus the Part B baseline score; a negative change indicates improvement. The change from baseline will be compared between the FMD-specific multidisciplinary rehabilitation arm and the conventional MS rehabilitation arm.
Time frame: From Part B baseline before randomization to the 3-month follow-up after randomization, ±14 days
Plan to share: No — No individual participant data-sharing plan has been finalized for this pilot multicenter study. Study results will be disseminated in aggregate or anonymized form in accordance with participant consent, Ethics Committee approval, applicable data-protection requirements, and institutional and interinstitutional agreements.
Start is estimated for Oct 2026; primary completion for May 2029, 31 months later.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 31 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.